Excitement for the SGLT2 inhibitor class continued at the 2019 ASN Kidney Week. Evidence continues to accumulate from analyses of the CREDENCE trial which originally showed - for the first time in a randomized controlled study with hard renal outcomes - that patients taking canagliflozin experienced slower decline in their kdiney function and a reduction in the incidence of end-stage renal failure requiring dialysis or kidney transplant. In the CREDENCE study, patients with an estimated eGFR below 30 ml/min were excluded from the trial. However, patients who had a eGFR > 30 ml/min at the time of screening but in whom the eGFR fell below 30 ml/min by the time of randomization were nevertheless included in the study.
UKidney Nephrology News and Insights
We are pleased to announce our collaboration with ConferenceInsider™ to bring you on-site coverage of ASN Kidney Week 2019 from our nation's capital. We'll bring you the heart of ASN Kidney Week 2019, from November 7 - 11, 2019. This is your direct connection to the most trusted and clinically relevant information about recent advances in the...
We are pleased to announce our collaboration with ConferenceInsider™ to bring you on-site coverage of ASN Kidney Week 2019 from our nation's capital. We'll bring you the heart of ASN Kidney Week 2019, from November 7 - 11, 2019. This is your direct connection to the most trusted and clinically relevant information about recent advances in the field of nephrology.
We'll continue to post educational session summaries and interviews with key opinion leaders throughout the conference – delivering the latest developments in nephrology medicine and patient care right to your email inbox. We want to hear from you, too. So be sure to share your opinions through our insightful daily polls.
If you’re not signed up already, please subscribe to UKidney to receive daily emails throughout ASN Kidney Week 2019. Each email will directly link to posted session updates. We hope you enjoy this resource!
The UKidney & ConferenceInsider Teams
Session: High-Impact Clinical Trials
Sub-session: Effects of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function and Damage in Type 2 Diabetes
Presenter: Ian H. de Boer, MD, MS, Division of Nephrology and Kidney Research Institute, University of Washington
It’s official. Two supplement darlings — Vitamin D and omega-3 fatty acid (often sold as fish oil) — do not help people with type 2 diabetes stave off chronic kidney disease. That’s according to a five-year study of kidney function, which included 1,312 adults with type 2 diabetes.
Session: Global Challenges of CKD
Sub-session: CKD in the United States and Europe: Juxtaposing the Epidemiology and Evolution
Presenter: Kitty J. Jager, MD, PhD, Academic Medical Center
There are marked differences in chronic kidney disease (CKD) prevalence and incidence trends between the Unites States and Europe. Even within countries there are enormous disparities.
During a deep dive into the granularity of available data, Kitty J. Jager, MD, PhD, Academic Medical Center, pointed out how, where, and sometimes why such differences in prevalence and incidence of CKD exist. Identifying and interpreting this data, Dr. Jager suggested, is critical to reducing the burden of CKD.
Poster: SIERRAS: A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in Subjects with ESRD on Stable Dialysis
Authors: Chaim Charytan, MD, Nephrology Associates, PC, New Rochelle, New York, et al
Roxadustat (ROXA) is an oral hypoxia–inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. And the drug — a novel first-in-class treatment for certain people with anemia from chronic kidney disease (CKD) — is being closely watched as its Phase III program pooled analyses continue to prompt headline-worthy news. In short, ROXA shows positive efficacy and no increased cardiovascular risk in patients with anemia from chronic kidney disease.
Session: Hot Off the Press: The Advancing American Kidney Health Initiative and More
Sub-Session: Deep Dive on New Kidney Care Delivery Models
Presenter: Tom Duvall, Acting Division Director for the Division of Special Populations and Projects at the Center for Medicare and Medicaid Innovation
Even on the final day of Kidney Week 2019, the remaining attendees’ energy level and riveted interest remained high — particularly in the morning session devoted to late-breaking developments in public policy. Case in point, the sub-session on new kidney care delivery models, present by Tom Duvall, Acting Division Director for the Division of Special Populations and Projects at the Center for Medicare and Medicaid Innovation (CMMI), which contains the CEC Model, the KCC Model, and the ETC Model.